Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II Trial of ZFA02-Adjuvanted Quadrivalent Influenza Vaccine
NCT06824519Phase 2Recruiting
- Sponsor
- Zhifei Biological
- Start
- May 2025
- Primary completion
- Aug 2025
- Modality
- Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of influenza vaccine + ZFA02 in influenza (14 arms), sponsored by Zhifei Biological. Primary endpoints: Adverse Events at 30 days, Adverse Events of Special Interest at 30 days and 10 more. Started May 2025; status: recruiting.
02
Drugs
influenza vaccine + ZFA02
03
Conditions
influenza
Beyond the preview
Go deeper on NCT06824519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06824519.